Preparing for a Post-Antibiotic Era

Developing Smart Therapeutics & Diagnostics

How is ARC Unique?


Antimicrobial Regeneration Consortium (ARC), founded in 2018, is an effort to streamline academic labs and industry towards accelerated discovery and development of antibiotics. The funding environment has shifted over the past few years with government sources becoming increasingly limited. At the same time, drug-resistant pathogens are exponentially increasing, causing innovation to severely lag behind evolution. In light of the urgency required for drug discovery and diagnostics but limited funding and the slow-pace of peer-review, there is need to develop an academic antibiotic innovation-accelerator.

ARC aims to:
1. Connect academic and medical expertise at various stages of drug design, development, and testing in around the world
2. Raise funding for accelerated drug-development by connecting with industry, government agencies, and private foundations
3. Generate and sustain start-up companies to commercialize new technology

To achieve these goals, ARC is assembling a team with expertise in diagnostics, drug development, drug-delivery, pharmacology, toxicology, host-pathogen interactions, clinical microbiology, microbiome, immunology, mathematical biology, product development, pre-clinical and clinical studies. ARC has five divisions where scientists and industry collaborate to develop antimicrobials and diagnostics.
A number of antibiotic resistance initiatives focusing on raising awareness have been taken across the globe, but an initiative that focuses on accelerated antibiotic and diagnostic development has not been created. The challenge of dealing with an evolving pathogen is unique, often one that cannot be solved using conventional approaches. Academia offers creative ideas to address antimicrobial resistance, but often lacks focus and resources to convert ideas into products that will reach patients. On the other hand, industry has the resources and focus for developing products, but is risk-averse in using unconventional approaches. ARC will, therefore, serve as a bridge between academia and industry, providing a clear and low-cost pathway to translate creative ideas into products, and thus offering an opportunity to solve an urgent health challenge we face as a human race.